Why Did Tonix Pharmaceuticals Holding Corp (TNXP) Plunge 7.77% Amid FDA Decision Fears?

On August 15, 2025, Tonix Pharmaceuticals Holding Corp (TNXP) experienced a significant drop of 7.77% in pre-market trading, sparking concerns among investors about the company's near-term prospects.

Recent price predictions for Tonix Pharmaceuticals Holding Corp (TNXP) have been mixed, with some analysts forecasting a 10.47% change over the next month, while others anticipate a more substantial 47.57% rise over the next three months. The stock's recent volatility has been driven by regulatory outcomes, particularly the upcoming FDA decision, which is seen as a key catalyst for the company's future performance.

Market focus remains on the regulatory outcomes, with the FDA ruling viewed as a critical factor in the stock's recent price movements. The stock has seen significant gains since a buy recommendation was issued, with a 62% increase in stock price. Analysts have issued various ratings, with Noble Capital Markets giving an "Outperform" rating on March 20, 2025. The consensus target price for Tonix Pharmaceuticals is $70.00, suggesting a potential upside of 17.49%.

Despite the recent drop, the overall trend for Tonix Pharmaceuticals Holding Corp (TNXP) is considered strongly bullish, with slight buying pressure observed. The company's position to invest in growth and its recent stock performance indicate that it is well-positioned to navigate the current market conditions.